Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molibresib - GlaxoSmithKline

Drug Profile

Molibresib - GlaxoSmithKline

Alternative Names: GSK-525762; GSK525762A; GSK525762C; IBET762

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Amides; Antineoplastics; Benzodiazepines; Small molecules; Triazoles
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer; Haematological malignancies; Solid tumours
  • Phase I/II Carcinoma
  • Phase I Prostate cancer

Most Recent Events

  • 09 Oct 2019 National Cancer Institute plans a phase I/II trial for Carcinoma (NUT carcinoma) (Combination therapy, Metastatic disease, Inoperable/unresectable) (NCI-2019-06676; 10295; NCT04116359)
  • 06 May 2019 Phase-II clinical trials in Acute myeloid leukaemia in Australia (PO, Tablet)
  • 24 Apr 2019 National Cancer Institute plans a phase I trial for Solid tumours and Lymphomas (Combination therapy, Late-stage disease, Second line therapy or greater) in May 2019 (PO) (NCT03925428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top